C21 Investments to be Acquired by Vireo Growth in All-Stock Deal
CXXIF sits 77% above its 52-week low of $0.145.
Summary
C21 Investments has entered into a definitive agreement to be acquired by Vireo Growth Inc. in an all-stock transaction, expanding Vireo's Nevada footprint.
Key Events · M&A and Partnerships · CXXIF
-
Definitive Acquisition Agreement
C21 Investments Inc. has entered into a definitive arrangement agreement to be acquired by Vireo Growth Inc. in an all-stock transaction.
-
All-Stock Consideration
C21 shareholders will receive 0.023052 of a Vireo subordinate voting share for each C21 share held.
-
Strategic Expansion in Nevada
The acquisition will expand Vireo's operating footprint in Nevada, adding 3 dispensaries and approximately 104,000 sq. ft. of cultivation and production capacity.
-
Board Approval and Shareholder Vote
The C21 Board unanimously approved the transaction, which requires C21 shareholder approval (expected Q3 2026), court, and regulatory approvals.
Analysis · CXXIF · Life Sciences
This definitive arrangement agreement means C21 Investments will be acquired by Vireo Growth, fundamentally changing the company's future. C21 shareholders will receive Vireo shares, gaining exposure to a larger multi-state cannabis operator. The deal is subject to shareholder and regulatory approvals, with a shareholder meeting expected in Q3 2026.
At the time of this filing, CXXIF was trading at $0.26 on OTC in the Life Sciences sector, with a market capitalization of approximately $55.8M. The 52-week trading range was $0.15 to $0.54. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.